

Damtix 200 mg/40 mg spot-on solution for dogs up to 4 kg

Authorised

- Permethrin (40:60)
- Imidacloprid

Product identification

Medicine name:

Damtix 200 mg/40 mg spot-on solution for dogs up to 4 kg

Active substance:

Permethrin (40:60)

Imidacloprid

Target species:

Dog

Route of administration:

Spot-on use

Product details

Active substance and strength:

Permethrin (40:60)

200.00 milligram(s) / 1.00 Pipette

Imidacloprid

40.00 milligram(s) / 1.00 Pipette

Pharmaceutical form:

Spot-on solution

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QP53AC54

Legal status of supply:

Veterinary medicinal product not subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Italy

Package description:

White polypropylene pipette closed with a polyethylene (HDPE) cap. Each pipette is packed in a polyethylene terephthalate/aluminium/low density polyethylene triplex bag. 1 ml pipette containing 0.4 ml of solution Box containing 1 pipette

White polypropylene pipette closed with a polyethylene (HDPE) cap. Each pipette is packed in a polyethylene terephthalate/aluminium/low density polyethylene triplex bag. 1 ml pipette containing 0.4 ml of solution Box containing 3 pipettes

White polypropylene pipette closed with a polyethylene (HDPE) cap. Each pipette is packed in a polyethylene terephthalate/aluminium/low density polyethylene triplex bag. 1 ml pipette containing 0.4 ml of solution Box containing 4 pipettes

White polypropylene pipette closed with a polyethylene (HDPE) cap. Each pipette is packed in a polyethylene terephthalate/aluminium/low density polyethylene triplex bag. 1 ml pipette containing 0.4 ml of solution Box containing 6 pipettes

White polypropylene pipette closed with a polyethylene (HDPE) cap. Each pipette is packed in a polyethylene terephthalate/aluminium/low density polyethylene triplex bag. 1 ml pipette containing 0.4 ml of solution Box containing 10 pipettes

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Hybrid application (Article 13(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

KRKA tovarna zdravil d.d. Novo mesto

Marketing authorisation date:

1/05/2023

Manufacturing sites for batch release:

KRKA tovarna zdravil d.d. Novo mesto

Responsible authority:

Ministry Of Health

Authorisation number:

105613

Date of authorisation status change:

1/05/2023

Reference member state:

Ireland

Procedure number:

IE/V/0663/001

Concerned member states:

Finland France Germany Greece Italy Portugal Spain

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 6/07/2025

[Download](#)

Summary of Product Characteristics